Patents by Inventor Carl Blobel

Carl Blobel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DAMAGE TO SKIN
    Publication number: 20220273679
    Abstract: A method and/or composition for treating or suppressing ultraviolet radiation sensitivity in a subject in need thereof. The method involves in one embodiment, administering a therapeutically effective amount of an agent which activates or increases the expression or activity of ADAM 17, or activates or increase the release of EGFR ligands, or increases epidermal EGFR in the subject's Langerhans cells. Compositions can include topical ointments, sunscreens, creams and sprays for topical application to the skin. These methods and compositions are useful particularly for patients with systemic lupus erythematosus, among other inflammatory skin conditions.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Inventors: Theresa T. Lu, Carl Blobel
  • PROTEIN BINDERS FOR IRHOM2
    Publication number: 20220204610
    Abstract: The present invention relates to a protein binder that binds to human iRhom2, and inhibits and/or reduces TACE/ADAM17 activity when bound to human iRhom2.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 30, 2022
    Inventors: Matthias Schneider, Kerstin Selle, Jens Ruhe, Gisela Weskamp, Carl Blobel
  • Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
    Patent number: 10024844
    Abstract: Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 17, 2018
    Assignees: Hospital for Special Surgery, University Health Network
    Inventors: Carl Blobel, Thorsten Maretzky, David McIlwain, Tak Wah Mak
  • TREATMENT OF EGF-RECEPTOR DEPENDENT PATHOLOGIES
    Publication number: 20150316538
    Abstract: Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 5, 2015
    Inventors: Carl Blobel, Thorsten Maretzky, David McIlwain, Tak Wah Mak
  • IRHOM2 INHIBITION FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20150241429
    Abstract: Disclosed are methods for treating a subject with a Complement mediated (e.g., C5a mediated) disease or an immune complex mediated disease. The method comprises the step of administering to the subject an effective amount of an agent that decreases the biological activity of iRhom2 or an agent that modulates formation of a complex between iRhom2 and TACE. Also disclosed are assays for identifying such agents.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 27, 2015
    Inventors: Priya Issuree, Thorsten Maretzky, David McIlwain, Tak Wah Mak, Carl Blobel, Jane Salmon